Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC).
暂无分享，去创建一个
C. Hudis | M. Blaney | I. C. Tudor | R. Nanda | T. Traina | L. Gianni | J. O’Shaughnessy | F. Ademuyiwa | A. Awada | P. Schmid | D. Yardley | M. Trudeau | C. Kelly | J. Cortés | Stephen Y. T. Chan | K. Miller | H. Uppal | L. García-Estévez | A. Peterson | J. Steinberg | S. Chan